Home / Business and Economy / AstraZeneca Beats Profit Estimates Amid Growth Concerns
AstraZeneca Beats Profit Estimates Amid Growth Concerns
27 Jul
Summary
- Second-quarter profit beat expectations with an 18% rise.
- Drugmaker reaffirms 2026 financial forecasts.
- Recent trial failure raises questions about long-term growth.
AstraZeneca reported strong second-quarter financial results, exceeding profit expectations. The company's core earnings saw an 18% increase, reaching $2.63 per share for the three months ending June 30. Total revenue also climbed by 5% to $15.38 billion at constant-currency rates, driven by robust demand for its cancer and rare disease therapies.
Despite these positive quarterly figures, AstraZeneca faces scrutiny over its future growth trajectory. An unexpected trial failure earlier this month has prompted concerns about the company's drug pipeline and its ability to achieve its longer-term revenue targets. However, the company reiterated its 2026 financial outlook.
AstraZeneca continues to project an increase in core earnings per share by a low double-digit percentage by 2026. Total revenues are expected to rise at a mid-to-high-single-digit rate in the same period. In 2025, the company had reported approximately 8% sales growth and 11% profit growth.
